Thomas P Ahern

List of Publications by Year
in descending order

50 papers	1,711 citations	394286 19 h-index	289141 40 g-index
50 all docs	50 docs citations	50 times ranked	2842 citing authors

#	Article	IF	Citations
1	Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. Journal of the National Cancer Institute, 2011, 103, 1461-1468.	3.0	308
2	Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncology, The, 2014, 15, e461-e468.	5.1	156
3	Post-Discharge Opioid Prescribing and Use after Common Surgical Procedure. Journal of the American College of Surgeons, 2018, 226, 1004-1012.	0.2	148
4	Use of β-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study. Journal of Clinical Oncology, 2013, 31, 2265-2272.	0.8	95
5	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology, 2017, 35, 1179-1188.	0.8	91
6	CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. Journal of the National Cancer Institute, 2011, 103, 489-500.	3.0	84
7	Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncológica, 2010, 49, 305-312.	0.8	82
8	Opioids and breast cancer recurrence: A Danish population-based cohort study. Cancer, 2015, 121, 3507-3514.	2.0	80
9	Statins: a role in breast cancer therapy?. Journal of Internal Medicine, 2018, 284, 346-357.	2.7	66
10	Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. British Journal of Cancer, 2008, 99, 616-621.	2.9	56
11	Impact of Acquired Comorbidities on All-Cause Mortality Rates Among Older Breast Cancer Survivors. Medical Care, 2009, 47, 73-79.	1.1	54
12	Use of antipsychotics and risk of breast cancer: a Danish nationwide case–control study. British Journal of Clinical Pharmacology, 2018, 84, 2152-2161.	1.1	37
13	Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. American Journal of Epidemiology, 2017, 186, 679-687.	1.6	32
14	Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. Breast Cancer Research and Treatment, 2014, 144, 427-435.	1.1	30
15	Cytochrome P-450 2D6 (*CYP2D6*) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. American Journal of Epidemiology, 2017, 185, 75-85.	1.6	30
16	Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget, 2017, 8, 112170-112183.	0.8	30
17	Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 938-944.	1.1	28
18	Lifetime tobacco smoke exposure and breast cancer incidence. Cancer Causes and Control, 2009, 20, 1837-1844.	0.8	23

#	Article	IF	Citations
19	Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction. Human Reproduction, 2018, 33, 503-511.	0.4	21
20	Postoperative opioid prescribing patterns and use after vascular surgery. Vascular Medicine, 2019, 24, 63-69.	0.8	19
21	Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clinical Epidemiology, 2010, 2, 241.	1.5	17
22	Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort. British Journal of Cancer, 2016, 114, 96-102.	2.9	17
23	The Association Between Vitamin K Antagonist Therapy and Site-specific Cancer Incidence Estimated by Using Heart Valve Replacement as an Instrumental Variable. American Journal of Epidemiology, 2011, 174, 1382-1390.	1.6	16
24	Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study. Annals of Oncology, 2014, 25, 2419-2425.	0.6	16
25	Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (*ProBeCaRe*) premenopausal breast cancer cohort study. Acta Oncológica, 2017, 56, 1155-1160.	0.8	14
26	Cumulative exposure to phthalates from phthalate–containing drug products: a Danish population–wide study. British Journal of Clinical Pharmacology, 2018, 84, 1798-1805.	1.1	14
27	Modification of Tamoxifen Response: What Have We Learned?. Journal of Clinical Oncology, 2008, 26, 1764-1765.	0.8	12
28	Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms. Journal of Clinical Pathology, 2017, 70, 428-434.	1.0	12
29	Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. Acta Oncológica, 2018, 57, 120-128.	0.8	12
30	Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. BMJ Open, 2018, 8, e021805.	0.8	11
31	Trends in breast-conserving surgery in Denmark, 1982–2002. European Journal of Epidemiology, 2008, 23, 109-114.	2.5	9
32	Towards a more precise and individualized assessment of breast cancer risk. Aging, 2019, 11, 1305-1316.	1.4	9
33	Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncológica, 2012, 51, 254-261.	0.8	8
34	Medication–Associated Phthalate Exposure and Childhood Cancer Incidence. Journal of the National Cancer Institute, 2022, 114, 885-894.	3.0	8
35	Manganese Superoxide Dismutase and Breast Cancer Recurrence: A Danish Clinical Registry-Based Case-Control Study, and a Meta-Analysis. PLoS ONE, 2014, 9, e87450.	1.1	6
36	Adjustment disorder and type-specific cancer incidence: a Danish cohort study. Acta Oncológica, 2018, 57, 1367-1372.	0.8	6

#	Article	IF	Citations
37	Circulating lipids, mammographic density, and risk of breast cancer in the Nurses' Health Study and Nurses' Health Study II. Cancer Causes and Control, 2019, 30, 943-953.	0.8	6
38	Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. PLoS ONE, 2017, 12, e0171453.	1.1	6
39	Ultrasound for the Objective Measurement of Breast Lymphedema. Journal of Ultrasound in Medicine, 2022, 41, 1993-2002.	0.8	6
40	Comment on 'Impact of *CYP2D6***10* on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'. Cancer Science, 2008, 99, 1706-1707.	1.7	5
41	Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin. Acta Oncológica, 2020, 59, 1009-1015.	0.8	5
42	Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. Acta Oncológica, 2016, 55, 734-741.	0.8	4
43	The impact of an acute care surgery model on general surgery service productivity. Perioperative Care and Operating Room Management, 2018, 12, 26-30.	0.2	4
44	Use of phthalate-containing prescription drugs and the risk of gastric cancer: a Danish nationwide case-control study. Acta Oncológica, 2019, 58, 852-858.	0.8	4
45	Pharmacoepidemiology in Pharmacogenetics. Advances in Pharmacology, 2018, 83, 109-130.	1.2	3
46	Expression of survivin does not appear to influence breast cancer recurrence risk. Acta Oncológica, 2019, 58, 154-161.	0.8	3
47	Bayesian Pathway Analysis for Complex Interactions. American Journal of Epidemiology, 2020, 189, 1610-1622.	1.6	3
48	Improving the transparency of meta-analyses with interactive web applications. BMJ Evidence-Based Medicine, 2021, 26, 327-332.	1.7	3
49	Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study. Pharmacoepidemiology and Drug Safety, 2019, 28, 528-535.	0.9	2
50	Reply to Ricci. Journal of Ultrasound in Medicine, 2022, , .	0.8	0